A5101455415- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal Cancer Treatments and Studies
- Gallbladder and Bile Duct Disorders
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Inflammatory Biomarkers in Disease Prognosis
- Hepatocellular Carcinoma Treatment and Prognosis
- Multiple and Secondary Primary Cancers
- Total Knee Arthroplasty Outcomes
- Cancer, Lipids, and Metabolism
- Asymmetric Synthesis and Catalysis
- Neuroendocrine Tumor Research Advances
- Knee injuries and reconstruction techniques
- Gestational Diabetes Research and Management
- Peptidase Inhibition and Analysis
- Chemical Synthesis and Analysis
- Orthopaedic implants and arthroplasty
- Lung Cancer Research Studies
- Metastasis and carcinoma case studies
- Cancer Research and Treatments
- Pharmacological Effects and Toxicity Studies
- RNA modifications and cancer
- Viral-associated cancers and disorders
Azienda Sanitaria Unità Locale di Reggio Emilia
2022-2024
Ospedale San Carlo
2024
Istituti di Ricovero e Cura a Carattere Scientifico
2011-2024
University of Modena and Reggio Emilia
2017-2023
Azienda Ospedaliero-Universitaria di Modena
2019-2021
European Institute of Oncology
2021
University of Florence
2021
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2021
Azienda Ospedaliero-Universitaria Careggi
2021
IRCCS Ospedale San Raffaele
2021
Abstract Background An accurate risk‐stratification is key to optimize the benefit‐to‐risk ratio of palliative treatment in advanced biliary cancer. We aimed at assessing impact prognostic nutritional index (PNI) on survival and response cancer (ABC) receiving first‐line chemotherapy. Methods Medical records ABC treated with standard chemotherapy Modena Cancer Centre were retrospectively reviewed for variables deemed potential interest, including PNI. Univariate multivariate analyses...
Background and aims The present study to investigate the role of prognostic nutritional index (PNI) on survival in patients with advanced hepatocellular carcinoma (HCC) treated sorafenib. Methods This multicentric included a training cohort 194 HCC three external validation cohorts 129, 76 265 Sorafenib, respectively. PNI was calculated as follows: 10 × serum albumin (g/dL) + 0.005 total lymphocyte count (per mm3). Univariate multivariate analyses were performed association between...
To evaluate the oncological and functional outcomes of transperineal laser ablation (TPLA) as focal therapy for localized prostate cancer (PCa) after a 12-month follow-up. Patients with low- intermediate-risk PCa were prospectively treated TPLA between July 2021 December 2022. The inclusion criteria following: clinical stage < T2b; PSA 20 ng/mL; International Society Urological Pathology (ISUP) grade ≤ 2; MRI-fusion biopsy-confirmed lesion classified PI-RADS v2.1 ≥ 3. Intra-, peri-,...
Background. Inadequate phosphorus control is associated with increased morbidity and mortality in patients CKD stage 5. Although phosphate binders are often used on peritoneal dialysis (PD), no large randomized controlled studies evaluating their use solely this population have previously been reported.
Objective Cytotoxic agents are the cornerstone of treatment for patients with advanced intrahepatic cholangiocarcinoma (iCCA), despite heterogeneous benefit. We hypothesised that pretreatment molecular profiles diagnostic biopsies can predict patient benefit from chemotherapy and define bases innate chemoresistance. Design identified a cohort iCCA comparable baseline characteristics who diverged as extreme outliers on (survival <6 m in rapid progressors, RP; survival >23 long...
BackgroundChemotherapy is the mainstay treatment for advanced biliary cancer (ABC). Best supportive care and clinical trials are currently alternative options. The identification of a prognostic score that can be widely applied to daily practice has potential better inform management ABC patients.MethodsA cohort 123 patients undergoing first-line chemotherapy was used as an exploratory define value laboratory tests routinely performed in practice. Kaplan–Meier analysis investigate...
Background. FOLFOXIRI plus Bevacizumab is one of the most frequently used first-line treatments for patients with BRAF-mutant colorectal cancer (CRC), while second-line treatment requires extensive further research. In this pooled analysis, we evaluate impact anti-angiogenics in pre-treated CRC. Methods. We monitored randomized, controlled studies who had advanced CRC and were undergoing chemotherapy addition to utilizing Bevacizumab, Ramucirumab or Aflibercept treatments. These data...
The synthesis of two new diastereomeric 6-amino-3-azabicyclo[3.2.1]octane-6-carboxylic acids exo- and endo-8,9 is reported using endo-norbornene amino as chiral building blocks. This method provides a fast access to optically pure 8 9 which can be considered both alpha,gamma- alpha,delta-diamino containing sterical constraints characterized by alpha,alpha-disubstitution.
Everolimus (Eve), which is a mammalian target of Rapamicin (mTOR) inhibitor, part the therapeutic armamentarium neuroendocrine tumors (NETs). Currently, there are no validated biomarkers predicting Eve efficacy in NETs. In this study, we explore whether expression phosphorilated (p)-mTOR and p70S6-kinase (S6K), downstream effector mTOR, correlates with outcome patients NET that were treated Eve.Tissue specimens derived from NETs at our Institution examined for levels p-mTOR p-S6K by...
This prospective study was created to evaluate the reliability of a new clinical test, which we termed "loss extension test" (LOE test). The LOE test investigates loss normal maximum passive (MPE) knee due an anterior cruciate ligament tear in comparison MPE healthy knee.The divided into two consecutive parts. Part 1 designed assess side-to-side difference population. In part 1, 100 adults were enrolled. 2 injured knees. 2, included 196 selected patients.In average population not...
Journal of Cancer Metastasis and Treatment is an open access journal, focusing on basic clinical studies related to cancer cell, cell biology, oncology, radiation therapy radiology, obstetrics gynecology, pediatrics, surgery, hematology, neuro-oncology, etc.